Current Problems in the Chemotherapy of Parasitic Diseases — The Role of the Pharmaceutical Industry

  • O. D. Standen
Part of the Chemotherapy book series (CT, volume 6)


The last decade has seen the progressive withdrawal of industrial Research and Development from the field of tropical parasitic disease. If the downward trend persists at the same rate, the already acute situation of absence of suitable drugs for control programmes in high prevalence diseases such as filariasis, schistosomiasis, malaria and trypanosomiasis could become irreversible. The reason for this withdrawal is essentially one of economics. Industry is concentrating its effort in disease areas offering reasonable chance of return on investment. The problem is how to equate the humanitarian needs of the increasing population of developing countries with the need for profitability adequate to maintain viability in industry. A possible answer lies in current WHO policy for establishing collaboration with industry and the recruitment of external expertise and funding supportive to industrial effort.


Drug Development Parasitic Disease Drug Resistant Strain Drug Registration Stanford Research Institute 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Davey, D.G. (1974) A.B.P.I. News (53), November 1974.Google Scholar
  2. 2.
    de Haen, P. (1973) “Pharmaceutical Specialities Marketed Nationally”. FDC Reports (Pink Sheet) 5th February 1973.Google Scholar
  3. 3.
    Stanford Research Institute. Report. The United States Health Product Market to 1980. June 1973.Google Scholar

Copyright information

© Springer Science+Business Media New York 1976

Authors and Affiliations

  • O. D. Standen
    • 1
  1. 1.The Wellcome Research LaboratoriesLangley CourtBeckenham, KentUK

Personalised recommendations